Why during a pandemic is the FDA not looking for s
Post# of 148122
Instead this seems to be up to the drug company and then for the FDA sit back and give a review on all the negative aspects.
I mean with Leronlimab shouldn't have been, "It seems to work up to here, but after 14 days it dropped off, should we try a bunch of patients with extended doses or higher doses?" Let's work on this "together" and see if we can get better results.